標(biāo)題: Titlebook: Renal Cell Carcinoma; Molecular Features a Mototsugu Oya Book 2017 Springer Japan KK 2017 Molecular-targeted therapy.TKI.anti-angiogenic ag [打印本頁] 作者: 使無罪 時間: 2025-3-21 16:14
書目名稱Renal Cell Carcinoma影響因子(影響力)
書目名稱Renal Cell Carcinoma影響因子(影響力)學(xué)科排名
書目名稱Renal Cell Carcinoma網(wǎng)絡(luò)公開度
書目名稱Renal Cell Carcinoma網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Renal Cell Carcinoma被引頻次
書目名稱Renal Cell Carcinoma被引頻次學(xué)科排名
書目名稱Renal Cell Carcinoma年度引用
書目名稱Renal Cell Carcinoma年度引用學(xué)科排名
書目名稱Renal Cell Carcinoma讀者反饋
書目名稱Renal Cell Carcinoma讀者反饋學(xué)科排名
作者: 我怕被刺穿 時間: 2025-3-21 23:50 作者: Melatonin 時間: 2025-3-22 01:39
Molecular Genetics of Renal Cell Carcinoma,and whole-genome sequencing, the genomic landscapes of renal cell carcinoma (RCC), consisting mainly of clear-cell, papillary (1 and 2), and chromophobe subtypes, have been characterized. This genomic information, coupled with DNA methylation, has shed light on the molecular biology of RCC and creat作者: Ptsd429 時間: 2025-3-22 04:41 作者: 預(yù)防注射 時間: 2025-3-22 10:42
Imaging Features of Renal Cell Carcinoma Differential Diagnosis, Staging, and Posttreatment Evaluatection of various subtypes of renal cell carcinomas (RCCs) and benign renal tumors. The differentiation of RCCs from benign tumors such as fat-poor angiomyolipoma and oncocytoma is very important to prevent unnecessary surgery. In addition, the recent progress of therapies to treat RCCs, including n作者: Fester 時間: 2025-3-22 14:29 作者: 外觀 時間: 2025-3-22 19:55
Natural History and Active Surveillance,is seen in cancers less than 4?cm. Surgery, either radical or partial nephrectomy, has been the mainstay of treatment of a small renal mass (SRM), defined as a usually incidentally discovered renal mass <4?cm in diameter which enhances on contrast imaging. There is morbidity associated with this sta作者: 和平主義者 時間: 2025-3-23 00:27
Surgical Treatment for Renal Cell Carcinoma,f renal cell carcinoma is an integral component of oncologic management. The spectrum of renal cell carcinoma presentation from small renal masses, locally advanced disease, and in the presence of metastasis varies with the surgical armamentarium needed to treat this diverse group of patients. In ge作者: GROG 時間: 2025-3-23 02:37 作者: 廢墟 時間: 2025-3-23 08:33
Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, and Pazopanib,ant improvement in patient outcomes. To date, targeting the vascular endothelial growth factor receptor (VEGFR) has been shown to lead to improved clinical outcomes in metastatic RCC. Currently, four VEGFR tyrosine kinase inhibitors (TKIs) have been approved by the Food and Drug Administration (FDA)作者: RALES 時間: 2025-3-23 12:18
Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus,ism; the mTOR pathway appears to be deregulated in a number of human malignancies including renal cell carcinoma..To date, two mTOR inhibitors have been registered for the treatment of renal cell carcinoma: temsirolimus (for treatment-na?ve patients with poor prognostic features) and everolimus (for作者: concubine 時間: 2025-3-23 17:51 作者: Ascendancy 時間: 2025-3-23 19:48 作者: 暴發(fā)戶 時間: 2025-3-23 23:06
Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy,t of advanced renal cell carcinoma (RCC). However, in most cases, RCC cells eventually develop drug resistance or drug treatments are stopped because of their adverse events (AEs)..TKIs that are selective for targeted molecules have potent antitumor effects and produce few side effects are ideal. Al作者: Hyperplasia 時間: 2025-3-24 03:12 作者: 是比賽 時間: 2025-3-24 09:32 作者: cumber 時間: 2025-3-24 14:04 作者: SOW 時間: 2025-3-24 14:53 作者: DRAFT 時間: 2025-3-24 21:57 作者: intercede 時間: 2025-3-25 00:33 作者: 膽小懦夫 時間: 2025-3-25 05:43
Surgical Treatment for Renal Cell Carcinoma,reductive nephrectomy has been shown to prolong survival in carefully selected patients, usually with good performance status and with oligometastasis. The surgical nuances, indication, and motivation for each surgical technique will be discussed in this chapter.作者: 無效 時間: 2025-3-25 08:08
Treatment for Non-clear Cell Renal Cell Carcinoma,ation to take the balance between each treatment arm. Many ongoing phase II trials should provide interesting preliminary insights into the antitumor efficacy of particular agents in these tumors. These approaches will lead us to improvements in the management of NCCRCC so as we have already achieved with the more common CCRCC.作者: 憤世嫉俗者 時間: 2025-3-25 14:53 作者: Agility 時間: 2025-3-25 19:11 作者: 節(jié)省 時間: 2025-3-25 22:38 作者: SPURN 時間: 2025-3-26 00:23 作者: 貧困 時間: 2025-3-26 07:29 作者: aggrieve 時間: 2025-3-26 12:06
Dae Y. Kim,Jose A. Karam,Christopher G. Wood MD, FACScribes how the data-path of a certain dig.ital block is generated using timing diagrams, a method which most textbooks do not cover, but is valuable in actual practice. ?In the end, the user is ready to use both the design methodology and the basic computing building blocks presented in the book to 作者: 狗窩 時間: 2025-3-26 12:50
Camillo Porta M.D.,Silvia Chiellino M.D.,Mimma Rizzo M.D.ce the complexity of the device by using fewer fuses than PLAs. As a result, most commercial implementations of programmable logic devices are PALs..Our discussion of ALU design suggest that complex digital circuit design can be simplified by using the higher level of abstraction provided by the com作者: crease 時間: 2025-3-26 18:44 作者: cancer 時間: 2025-3-27 00:37 作者: 噴出 時間: 2025-3-27 04:44
Keiichi Itoce the complexity of the device by using fewer fuses than PLAs. As a result, most commercial implementations of programmable logic devices are PALs..Our discussion of ALU design suggest that complex digital circuit design can be simplified by using the higher level of abstraction provided by the com作者: 我悲傷 時間: 2025-3-27 05:45 作者: 匍匐前進(jìn) 時間: 2025-3-27 10:24 作者: 特征 時間: 2025-3-27 16:00
Epidemiology of Renal Cell Carcinoma,t RCC risk. Other risk factors that have been implicated include type II diabetes?and other chronic medical conditions, occupational/environmental exposures, parity, and number of offspring. Recent genome-wide association studies (GWAS) have identified multiple chromosome regions harboring RCC susce作者: 有毛就脫毛 時間: 2025-3-27 18:49
Hereditary Renal Cell Carcinoma,wden syndrome (CS), and BAP1 cancer susceptibility syndrome. All of these syndromes are associated with a germline mutation in a specific causative gene and are inherited in an autosomal dominant manner. In this chapter, clinical manifestations, genetics, and molecular functions of the responsible g作者: Harness 時間: 2025-3-28 00:55 作者: Aphorism 時間: 2025-3-28 05:09 作者: 惡心 時間: 2025-3-28 09:24
Treatment Overview,tients with benign tumors. As for systemic therapy, introduction of targeted therapy has prolonged the survival of patients with metastatic RCC compared to that of the cytokine era. In addition, immune checkpoint inhibitors have recently introduced a major paradigm shift in sequential therapy. These作者: GROWL 時間: 2025-3-28 13:56 作者: 邊緣帶來墨水 時間: 2025-3-28 17:21
Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma,were identified as key prognostic features. Patients were segregated into three risk categories: favorable (0 risk factors median overall survival (mOS) of 43.2?months), intermediate (one to two risk factors; mOS 22.5?months), and poor risk group (three or more risk factors; mOS 7.8?months). Also th作者: Asseverate 時間: 2025-3-28 18:57
Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus,ent settings, yielding conflicting results. Further development of these two drugs in renal cell carcinoma is expected, even though only the identification of reliable genetic or molecular biomarkers will lead to a tailored, and thus smarter, use of these drugs.作者: 格子架 時間: 2025-3-28 23:49 作者: Blood-Clot 時間: 2025-3-29 05:46 作者: 禁止,切斷 時間: 2025-3-29 08:38
Book 2017ndocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistanc作者: 機(jī)密 時間: 2025-3-29 14:11 作者: colony 時間: 2025-3-29 18:37
Jaimin R. Bhatt,Patrick O. Richard,Michael A. S. Jewett method which most textbooks do not cover, but is valuable in actual practice. ?In the end, the user is ready to use both the design methodology and the basic computing building blocks presented in the book to 978-3-319-25811-9作者: 清澈 時間: 2025-3-29 21:09 作者: Gobble 時間: 2025-3-30 02:47 作者: Palliation 時間: 2025-3-30 07:26
https://doi.org/10.1007/978-4-431-55531-5Molecular-targeted therapy; TKI; anti-angiogenic agent; mTOR inhibitors; tyrosine-kinase inhibitors作者: 合適 時間: 2025-3-30 11:30 作者: 基因組 時間: 2025-3-30 14:08 作者: 治愈 時間: 2025-3-30 17:23
Masahiro Jinzaki,Hirotaka Akita,Mototsugu Oyaarchitectural specifications.Focuses not only on CPU architeThis textbook provides semester-length coverage of computer architecture and design, providing a strong foundation for students to understand modern computer system architecture and to apply these insights and principles to future computer 作者: 真繁榮 時間: 2025-3-31 00:37 作者: 女上癮 時間: 2025-3-31 01:22
Jaimin R. Bhatt,Patrick O. Richard,Michael A. S. Jewettarchitectural specifications;.Focuses not only on CPU architThis textbook provides semester-length coverage of computer architecture and design, providing a strong foundation for students to understand modern computer system architecture and to apply these insights and principles to future computer
